JPWO2020243448A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020243448A5 JPWO2020243448A5 JP2021570756A JP2021570756A JPWO2020243448A5 JP WO2020243448 A5 JPWO2020243448 A5 JP WO2020243448A5 JP 2021570756 A JP2021570756 A JP 2021570756A JP 2021570756 A JP2021570756 A JP 2021570756A JP WO2020243448 A5 JPWO2020243448 A5 JP WO2020243448A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- sequence
- actriib
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025067310A JP2025118664A (ja) | 2019-05-30 | 2025-04-16 | Ａｃｔｒｉｉ結合性タンパク質及びその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962854625P | 2019-05-30 | 2019-05-30 | |
| US62/854,625 | 2019-05-30 | ||
| PCT/US2020/035148 WO2020243448A1 (en) | 2019-05-30 | 2020-05-29 | Actrii-binding proteins and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025067310A Division JP2025118664A (ja) | 2019-05-30 | 2025-04-16 | Ａｃｔｒｉｉ結合性タンパク質及びその使用 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022534966A JP2022534966A (ja) | 2022-08-04 |
| JPWO2020243448A5 true JPWO2020243448A5 (https=) | 2023-06-06 |
| JP2022534966A5 JP2022534966A5 (https=) | 2023-06-06 |
| JP7669291B2 JP7669291B2 (ja) | 2025-04-28 |
Family
ID=73553540
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021570756A Active JP7669291B2 (ja) | 2019-05-30 | 2020-05-29 | Ａｃｔｒｉｉ結合性タンパク質及びその使用 |
| JP2025067310A Pending JP2025118664A (ja) | 2019-05-30 | 2025-04-16 | Ａｃｔｒｉｉ結合性タンパク質及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025067310A Pending JP2025118664A (ja) | 2019-05-30 | 2025-04-16 | Ａｃｔｒｉｉ結合性タンパク質及びその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US12545736B2 (https=) |
| EP (1) | EP3976630A4 (https=) |
| JP (2) | JP7669291B2 (https=) |
| KR (1) | KR20220029563A (https=) |
| CN (1) | CN114127087A (https=) |
| AU (1) | AU2020284038A1 (https=) |
| CA (1) | CA3142149A1 (https=) |
| WO (1) | WO2020243448A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020284038A1 (en) | 2019-05-30 | 2021-12-02 | Acceleron Pharma Inc. | ActRII-binding proteins and uses thereof |
| JP2024511315A (ja) * | 2021-03-10 | 2024-03-13 | アクセルロン ファーマ インコーポレイテッド | Ａｃｔｒｉｉ－ａｌｋ４アンタゴニスト及び心不全の治療方法 |
| US20250064952A1 (en) * | 2021-03-10 | 2025-02-27 | Acceleron Pharma Inc. | Actrii-alk4 antagonists and methods of treating heart failure |
| JP2024532345A (ja) * | 2021-09-03 | 2024-09-05 | ラエクナ セラピューティクス シャンハイ カンパニー リミテッド | 抗ａｃｖｒ２ａ抗体及びその使用 |
| AU2024317572A1 (en) | 2023-07-31 | 2026-03-12 | Sixpeaks Bio Ag | Antibody conjugates and fusion proteins |
| WO2025026353A1 (en) * | 2023-08-01 | 2025-02-06 | Laekna Therapeutics Shanghai Co., Ltd. | Anti-acvr2b antibodies and uses thereof |
| WO2025068454A1 (en) * | 2023-09-28 | 2025-04-03 | Sixpeaks Bio Ag | Antibodies targeting actriia and actriib |
| CN121344183B (zh) * | 2025-12-18 | 2026-03-27 | 成都医学院 | 检测ACVR2b的试剂在制备慢性肾脏病血管钙化诊断试剂盒中的用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CL2007002567A1 (es) | 2006-09-08 | 2008-02-01 | Amgen Inc | Proteinas aisladas de enlace a activina a humana. |
| JP5766179B2 (ja) | 2009-04-27 | 2015-08-19 | ノバルティス アーゲー | 筋肉増殖を増加させるための組成物および方法 |
| US8765385B2 (en) | 2011-10-27 | 2014-07-01 | Ravindra Kumar | Method of detection of neutralizing anti-actriib antibodies |
| GR1007832B (el) | 2011-11-21 | 2013-02-14 | Ιδρυμα Ιατροβιολογικων Ερευνων Ακαδημιας Αθηνων, | Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη" |
| JP2015525230A (ja) | 2012-06-11 | 2015-09-03 | アムジエン・インコーポレーテツド | デュアル受容体アンタゴニスト性抗原結合タンパク質およびその使用 |
| WO2014172448A2 (en) * | 2013-04-17 | 2014-10-23 | Anaptysbio, Inc. | Antibodies directed against activin receptor type ii (actrii) |
| TW201920262A (zh) | 2013-07-30 | 2019-06-01 | 美商再生元醫藥公司 | 抗活化素ａ之抗體及其用途 |
| PT3286206T (pt) | 2015-04-22 | 2021-04-01 | Biogen Ma Inc | Novas proteínas híbridas bloqueadoras de ligando actriib para tratar doenças de desgaste muscular |
| AU2017222526A1 (en) | 2016-02-22 | 2018-08-23 | Acceleron Pharma Inc. | ActRII antagonists for use in increasing immune activity |
| JP6987072B2 (ja) * | 2016-03-10 | 2021-12-22 | アクセレロン ファーマ インコーポレーテッド | アクチビン２型受容体結合タンパク質及びその使用 |
| FI3600415T3 (fi) | 2017-03-24 | 2025-12-05 | Novartis Ag | Aktiviinireseptorin tyypin ii reseptorin vastainen vasta-aine käytettäväksi sydämen vajaatoiminnan hoidossa |
| AU2020284038A1 (en) | 2019-05-30 | 2021-12-02 | Acceleron Pharma Inc. | ActRII-binding proteins and uses thereof |
-
2020
- 2020-05-29 AU AU2020284038A patent/AU2020284038A1/en active Pending
- 2020-05-29 KR KR1020217040678A patent/KR20220029563A/ko active Pending
- 2020-05-29 EP EP20814343.8A patent/EP3976630A4/en active Pending
- 2020-05-29 WO PCT/US2020/035148 patent/WO2020243448A1/en not_active Ceased
- 2020-05-29 CA CA3142149A patent/CA3142149A1/en active Pending
- 2020-05-29 CN CN202080051148.1A patent/CN114127087A/zh active Pending
- 2020-05-29 US US17/615,474 patent/US12545736B2/en active Active
- 2020-05-29 JP JP2021570756A patent/JP7669291B2/ja active Active
-
2025
- 2025-04-16 JP JP2025067310A patent/JP2025118664A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024026159A5 (https=) | ||
| JP6585503B2 (ja) | ヘテロ二量体免疫グロブリン | |
| CN102037016B (zh) | 针对粒细胞巨噬细胞集落刺激因子的抗体 | |
| JP2019513015A5 (https=) | ||
| JP7766392B2 (ja) | 治療用抗ｃｄ４０リガンド抗体 | |
| TW202221043A (zh) | PD-1/TGF-beta四價雙特異性抗體、其製備方法和用途 | |
| WO2019195313A1 (en) | Anti-vegf antagonist and pedf agonist constructs and uses thereof | |
| JP2019515676A5 (https=) | ||
| JP2021500895A5 (https=) | ||
| JPWO2020243448A5 (https=) | ||
| EP3577136A1 (en) | Inhibition of platelet aggregation using anti-human gpvi antibodies | |
| US20250257140A1 (en) | Bispecific agonistic antibodies to activin a receptor like type 1 (alk1) | |
| CN115811987A (zh) | 抗神经酰胺抗体 | |
| US20260109769A1 (en) | Pd-1 bnding proteins, vegf and pd-1 bispecific binding proteins, compositions, and methods of use | |
| JPWO2022253314A5 (https=) | ||
| WO2026080748A2 (en) | Bone morphogenetic protein receptor type 2 (bmprii) antibodies | |
| WO2026080752A2 (en) | De novo antibodies to activin a receptor like type 1 (alk1) | |
| JPWO2020243443A5 (https=) | ||
| WO2026080757A2 (en) | Activin receptor type ii a/b (actriia/b) antibodies | |
| TW202523697A (zh) | 抗ｔｓｌｐ抗體構築體及其用途 | |
| TW202409093A (zh) | 融合蛋白 |